When I was diagnosed with neuromyelitis optica (NMO) in 2012, the U.S. Food and Drug Administration (FDA) hadn’t yet approved any medications specifically to treat this disease. However, doctors could select various therapies to help patients prevent or deal with attacks. When NMO patients had an attack, doctors treated…
treatment
Enspryng has been approved by the Taiwan Food and Drug Administration for treating people 12 and older who have aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), Chugai Pharmaceutical announced. The import drug license…
Recent Posts
- Treatment linked to fewer NMOSD relapses, less steroid use in study
- Navigating NMOSD at the intersection of culture and family
- Review shows approved treatment sharply cuts relapse risk in NMOSD
- Choosing courage and connection after the trauma of NMOSD
- NMOSD patients report lower sleep quality, study shows